← All trials
NCT05087030
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 21, 2021
- Primary completion
- Jun 30, 2023
- Completion date
- Oct 30, 2023
- First posted
- Oct 21, 2021
- Last posted
- Oct 21, 2021
- Enrollment
- 434
- Arms / groups
- 5 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Gedeon Richter Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.